Abstract: A surgical instrument, has an end effector that includes an ultrasonic blade, and a clamp arm that moves relative to the ultrasonic blade from an opened position toward an intermediate position and a closed position. The clamp arm is offset from the ultrasonic blade to define a predetermined gap in the intermediate position between the opened position and the closed position. A clamp arm actuator connects to the clamp arm and moves from an opened configuration to a closed configuration to direct the clamp arm from the opened position toward the intermediate position and the closed position. A spacer connects with the clamp arm to inhibit movement of the clamp arm from the intermediate position toward the closed position for maintaining the predetermined gap between the clamp arm and the ultrasonic blade.

Abstract: A powered fastener driver includes a driver blade movable from a top-dead-center (TDC) position to a bottom-dead-center (BDC) position for driving a fastener into a workpiece and a drive unit for providing torque to move the driver blade from the BDC position toward the TDC position. A rotary lifter is engageable with the driver blade and configured to receive torque from the drive unit for returning the driver blade from the BDC position toward the TDC position. The lifter has a body, a drive pin coupled to the body, and a roller positioned on the drive pin. The roller includes an engagement section configured to receive an end portion of a tooth of the driver blade. The lifter includes a means for aligning the engagement section with the end portion of the tooth on the driver blade to facilitate meshing between the end portion and the roller.

Abstract: Provided is a wall grommet, which can be installed through the surfaces of walls to route wiring in the walls' interior spaces. In particular, the wall grommet is configured for running power cords inside walls and presenting the electrical connectors of a power cord in a manner such that power cords are hidden from view. The grommet may comprise a housing, which defines an interior space that is adapted to hold either the female connector or male connector of a power cord. The housing may be configured to enclose and secure the electrical connector of the power cord in the housing.

Abstract: Antimicrobial compositions used to form a residual dry-coat include a halo active aromatic sulfonamide compound of Formula (I): wherein the variables R1, R2, R3, R4, R5, X, M and n are disclosed herein. The compositions and processes utilizing the same can be used as a dry coating or layer to maintain disinfected surfaces with reduced microbial count over extended time periods ranging from multiple days up to several weeks.

Abstract: Disclosed herein are compositions useful for the treatment and/or prevention of various diseases and conditions, including a variety of infections, via internal administration to a patient. The compositions comprise an effective amount of a halo active aromatic sulfonamide compound having the structure of Formula (I): wherein R1, R2, R3, R4, and R5, X, and M are defined herein. The compositions described may be used to treat and/or prevent a variety of infections, including bacterial infections, viral infections, fungal infections, and the like. The compositions can be internally administered to a patient via at least one of: oral administration, pulmonary administration, subcutaneous administration, sublingual administration, ocular administration, otic administration, intravenous administration, inter-dermal administration, epidural administration, intraperitoneal administration, and intramuscular administration.

Abstract: Disclosed herein are compositions useful for the treatment and/or prevention of various skin conditions, including infections, via external and/or topical administration to a patient. The compositions comprise an effective amount of a halo active aromatic sulfonamide compound having the structure of Formula (I): wherein R1, R2, R3, R4, and R5, X, and M are defined herein. The compositions described may be used to treat and/or prevent a variety of skin conditions, including acne, eczema, rosacea, hives, psoriasis, athlete's foot, candidiasis, shingles, chicken pox, cold sores, bacterial infections, viral infections, fungal infections, and the like. The compositions can be externally and/or topically administered to a patient, for example, as a spray or a wipe. Further, the compositions can also be externally and/or topically administered to a patient by, for example, applying the composition to a medical device that is then implanted into the patient or contacted with the patient.

Abstract: Articles are treated with a reduced amount of a halo active aromatic sulfanomide compound of Formula (I): wherein R1, R2, R3, R4, and R5 are independently selected from hydrogen, COOR?, CON(R?)2, alkoxy, CN, NO2, SO3R?, halogen, substituted or unsubstituted phenyl, sulfonamide, halosulfonamide, and substituted or unsubstituted C1-C12 alkyl; R? is hydrogen, an alkali metal, an alkaline earth metal, substituted C1-C12 alkyl, or unsubstituted C1-C12 alkyl; and R? is hydrogen or substituted or unsubstituted C1-C12 alkyl, where the two R? groups in CON(R?)2 may be independently selected; X is halogen; M is an alkali or alkaline earth metal; and n is the number of water molecules per molecule of the sulfonamide compound. The compound effectively suppresses odors pre-use, in use, and post-use for extended periods of time.

Abstract: Antimicrobial compositions used to form a residual dry-coat include a halo active aromatic sulfonamide compound of Formula (I): wherein the variables R1, R2, R3, R4, R5, X, M and n are disclosed herein. The compositions and processes utilizing the same can be used as a dry coating or layer to maintain disinfected surfaces with reduced microbial count over extended time periods ranging from multiple days up to several weeks.

Abstract: A filter is treated with a reduced amount of a halo active aromatic sulfanomide compound of Formula (I): wherein R1, R2, R3, R4, and R5 are independently selected from hydrogen, COOR?, CON(R?)2, alkoxy, CN, NO2, SO3R?, halogen, substituted or unsubstituted phenyl, sulfonamide, halosulfonamide, and substituted or unsubstituted C1-C12 alkyl; R? is hydrogen, an alkali metal, an alkaline earth metal, substituted C1-C12 alkyl, or unsubstituted C1-C12 alkyl; and R? is hydrogen or substituted or unsubstituted C1-C12 alkyl, where the two R? groups in CON(R?)2 may be independently selected; X is halogen; M is an alkali or alkaline earth metal; and n is the number of water molecules per molecule of the sulfonamide compound. The compound effectively suppresses odors pre-use, in use, and post-use for extended periods of time.

Abstract: Articles are treated with a reduced amount of a halo active aromatic sulfanomide compound of Formula (I): wherein R1, R2, R3, R4, and R5 are independently selected from hydrogen, COOR?, CON(R?)2, alkoxy, CN, NO2, SO3R?, halogen, substituted or unsubstituted phenyl, sulfonamide, halosulfonamide, and substituted or unsubstituted C1-C12 alkyl; R? is hydrogen, an alkali metal, an alkaline earth metal, substituted C1-C12 alkyl, or unsubstituted C1-C12 alkyl; and R? is hydrogen or substituted or unsubstituted C1-C12 alkyl, where the two R? groups in CON(R?)2 may be independently selected; X is halogen; M is an alkali or alkaline earth metal; and n is the number of water molecules per molecule of the sulfonamide compound. The compound effectively suppresses odors pre-use, in use, and post-use for extended periods of time.

Abstract: Processes for extracting iodine from an aqueous solution, such as brine, are disclosed. Activated coconut carbon particles are mixed with the solution to adsorb iodide through pores in the activated carbon particles. The activated carbon particles are then treated with sulfur dioxide gas and water to form hydrogen iodide. The hydrogen iodide is then reacted with chloride to obtain elemental iodine (I2).

Abstract: Articles are treated with a reduced amount of a halo active aromatic sulfonamide compound of Formula (I): wherein R1, R2, R3, R4, and R5 are independently selected from hydrogen, COOR?, CON(R?)2, alkoxy, CN, NO2, SO3R?, halogen, substituted or unsubstituted phenyl, sulfonamide, halosulfonamide, and substituted or unsubstituted C1-C12 alkyl; R? is hydrogen, an alkali metal, an alkaline earth metal, substituted C1-C12 alkyl, or unsubstituted C1-C12 alkyl; and R? is hydrogen or substituted or unsubstituted C1-C12 alkyl, where the two R? groups in CON(R?)2 may be independently selected; X is halogen; M is an alkali or alkaline earth metal; and n is the number of water molecules per molecule of the sulfonamide compound. The compound effectively suppresses odors pre-use, in use, and post-use for extended periods of time.

Abstract: A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of between about 25 ?g/kg, and 2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 ?g/kg/min, wherein the active drug is tirofiban or a salt thereof.

Abstract: A filter is treated with a reduced amount of a halo active aromatic sulfanomide compound of Formula (I): wherein R1, R2, R3, R4, and R5 are independently selected from hydrogen, COOR?, CON(R?)2, alkoxy, CN, NO2, SO3R?, halogen, substituted or unsubstituted phenyl, sulfonamide, halosulfonamide, and substituted or unsubstituted C1-C12 alkyl; R? is hydrogen, an alkali metal, an alkaline earth metal, substituted C1-C12 alkyl, or unsubstituted C1-C12 alkyl; and R? is hydrogen or substituted or unsubstituted C1-C12 alkyl, where the two R? groups in CON(R?)2 may be independently selected; X is halogen; M is an alkali or alkaline earth metal; and n is the number of water molecules per molecule of the sulfonamide compound. The compound effectively suppresses odors pre-use, in use, and post-use for extended periods of time.

Abstract: A system and method for soft tissue repair. According to one embodiment, sensing gauges or other sensing technologies are utilized at distal ends of jaws, passing a needle or within the instrument to identify tissue differences that give the end user feedback on these differences. A console connected to the instrument assists in utilizing sensing technology to give the end user feedback on tissue differences.

Abstract: An odor-controlling bodily fluid absorbent member comprises (a) an absorbent material or substrate; and (b) a halo active aromatic sulfonamide compound of Formula (I): wherein R1, R2, R3, R4, R5, X, M, and n are as described herein; and wherein at least one of R1, R2, R3, R4, and R5 is not hydrogen. The absorbent member effectively controls odor arising from various body fluids.

Abstract: Articles are treated with a reduced amount of a halo active aromatic sulfonamide compound of Formula (I): wherein R1, R2, R3, R4, and R5 are independently selected from hydrogen, COOR?, CON(R?)2, alkoxy, CN, NO2, SO3R?, halogen, substituted or unsubstituted phenyl, sulfonamide, halosulfonamide, and substituted or unsubstituted C1-C12 alkyl; R? is hydrogen, an alkali metal, an alkaline earth metal, substituted C1-C12 alkyl, or unsubstituted C1-C12 alkyl; and R? is hydrogen or substituted or unsubstituted C1-C12 alkyl, where the two R? groups in CON(R?)2 may be independently selected; X is halogen; M is an alkali or alkaline earth metal; and n is the number of water molecules per molecule of the sulfonamide compound. The compound effectively suppresses odors pre-use, in use, and post-use for extended periods of time.

Abstract: A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of between about 25 ?g/kg, and 2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 ?g/kg/min, wherein the active drug is tirofiban or a salt thereof.

Abstract: Aromatic N-halosulfonamide organic compounds have been known for over one hundred years. The ability of these compounds to release active halogen ions has been utilized in a range of biocidal and fungicidal applications. This disclosure deals with the use of halo active aromatic sulfonamide organic compounds as odor control and/or biocidal agents in a cleaning solution for use with bovines and other dairy animals.

Abstract: Aromatic N-halosulfonamide organic compounds have been known for over one hundred years. The ability of these compounds to release active halogen ions has been utilized in a range of biocidal and fungicidal applications. This disclosure deals with the use of halo active aromatic sulfonamide organic compounds as odor control and/or biocidal agents in a cleaning solution for use with bovines and other dairy animals.